Examining the Use of Real‐World Evidence in the Regulatory Process
Clinical Pharmacology & Therapeutics2019Vol. 107(4), pp. 843–852
Citations Over TimeTop 1% of 2019 papers
Brett K. Beaulieu‐Jones, Samuel G. Finlayson, William Yuan, Russ B. Altman, Isaac S. Kohane, Vinay Prasad, Kun‐Hsing Yu
Abstract
The 21st Century Cures Act passed by the United States Congress mandates the US Food and Drug Administration to develop guidance to evaluate the use of real-world evidence (RWE) to support the regulatory process. RWE has generated important medical discoveries, especially in areas where traditional clinical trials would be unethical or infeasible. However, RWE suffers from several issues that hinder its ability to provide proof of treatment efficacy at a level comparable to randomized controlled trials. In this review article, we summarized the advantages and limitations of RWE, identified the key opportunities for RWE, and pointed the way forward to maximize the potential of RWE for regulatory purposes.
Related Papers
- → ESKVS: efficient and secure approach for keyframes-based video summarization framework(2024)9 cited
- Using DataGrid Control to Realize DataBase of Querying in VB6.0(2000)
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)